Introduction
Autoimmune hepaitits (AIH) is an immune-mediated liver disease which can present in acute or chronic forms, and may lead to cirrhosis and liver failure if untreated. It is characterised by elevated transaminases, raised Immunoglobulin G levels, histological features of interface hepatitis with a lymphoplasmacytic infiltration and the presence of autoantibodies in serum (1-3).
The diagnosis and management of AIH could be challenging as AIH represents a chameleon disease with protean clinical manifestation and significant heterogeneity in relation to clinical course and outcome. Indeed, the clinical features are not confined to the liver. Concurrent extrahepatic autoimmune disorders (CEHAID) including autoimmune thyroiditis, connective tissue disease and inflammatory bowel disease are frequently associated with AIH. CEHAID may predate, coincide or even occur years after the diagnosis of AIH. This association has been recognised and incorporated into the original and revised International Autoimmune Hepatitis Group (IAIHG) scoring systems as an aid to codifing the diagnosis (4, 5) . The frequency of CEHAID in AIH has been derived predominantly from case reports (6) (7) (8) (9) (10) (11) (12) and a few cohort studies (13) (14) (15) . Large cohort studies to systematically assess the features and effect of CEHAID in AIH are lacking.
On the other aspect, since AIH arises in genetically susceptible individuals, there may be a close relationship between personal and familial hepatic and extrahepatic autoimmunity.
Although up to 43% of AIH patients have been reported to have a family history of CEHAID
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in their first degree relatives, commonly with thyroid disease and type 1 diabetes (16, 17) , the association of extrahepatic autoimmunity among AIH patients and their family especially first degree relatives remains unexplored.
In this study, we sought to describe the patterns of CEHAID, the association of personal and familial extrahepatic autoimmunity in AIH and finally to evaluate the impact of CEHAID, if any, on the clinical course and long term outcomes.
Patients and Methods
Two well-established and updated databases of patients with AIH attending the Finally, two groups of AIH patients with and without CEHAID were compared in relation to the clinical, laboratory and histological features, response to therapy, clinical outcomes and survival.
As described in our previous studies, standard diagnostic criteria for the presence of AIH was fulfilled (18) (19) (20) . There was no corroborative history of concomitant use of hepatotoxic drugs except for eleven patients who had diagnosis of drug-induced AIH (20) .
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Liver biopsy was available at diagnosis in 471(83.8%) of 562 patients with AIH. Histological assessment of the severity of liver inflammation and the degree of fibrosis was based on the scoring system proposed by Batts and Ludwig (21) . In this system, necroinflammatory activity is graded as 0 = none, 1= minimal, 2 = mild, 3 = moderate and 4 = marked activity +/-bridging collapse or multiacinar necrosis, whereas the degree of fibrosis is staged as 0 = none, 1 = portal, 2 = periportal, 3 = septal/bridging fibrosis including incomplete cirrhosis and 4 = cirrhosis.
AIH-1 was defined by the presence of antinuclear antibody (ANA) or smooth muscle antibody (SMA) or both. AIH-2 and autoantibody negative AIH were classified by the presence of anti-liver-kidney microsomal-1 (anti-LKM1) and absence of all the autoantibodies described respectively. Associated diagnosis of CEHAID and family history of autoimmune diseases were searched and retrieved via the the hospital electronic records, clinical letters and medical casenotes. All these diseases have been diagnosed and confirmed based on the international criteria, when available.
Time to diagnosis was defined as the time from the first onset of symptoms or first detection of liver dysfunction to the formal diagnosis of AIH. The mode of presentation refered to the acuity of the initial illness or symtomatology, and was defined as 'acute' if symptom onset to diagnosis was ≤ 6 months, 'insidious'> 6 months and 'asymptomatic' if the patients had no obvious signs or symptoms of liver disease and the diagnosis of AIH was first discovered based on the incidental finding of abnormal liver tests either during routine health screening or during evaluation of a non-hepatic illness. Follow-up duration was defined as the time of the diagnosis was first made until the last outpatient appointment in the clinic, or death or liver transplantation (LT) (18, 19) .
All patients with AIH were treated according to standardised protocols published previously (18, 19, 22) . Response to treatment and relapse were defined in accordance with the revised criteria of the IAIHG (5), and partial or no response to initial therapy according to the original criteria (4).
Disease progression was defined as the development of cirrhosis in non-cirrhotic patients based on imaging and/or histology during follow-up, worsening of the fibrosis scores on repeat histology, when available, despite on optimum immuosuppression, and the occurrence of clinically significant liver-related complications including episodes of decompensation, development of hepatocellular carcinoma (HCC), death or LT in cirrhotic patients. 
Statistical analysis
Results were analysed using SPSS version 21.0 (IBM Corp, Armonk NY).
Continuous variables were expressed as median (range). Categorical variables are expressed as actual numbers and percentages. Analysis of variance was used to compare the differences in variable between the two groups. Group comparisons of categorical variables were analysed with χ2-test or Fisher's exact test if the expected cell frequency is less than 5. The Mann-Whitney test was used for the evaluation of continuous variables.
End-points and censoring date for survival analysis were taken as the time of most recent clinic visit or date of death or LT. Death from complications of cirrhosis, progressive liver failure and HCC were considered to be liver-related. Survival rates between 2 groups of
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AIH patients with and without CEHAID were calculated according to the Kaplan-Meier method and compared using the log-rank test. Univariate analysis using Cox's proportional hazards regression model for survival analysis was adopted to assess the predictive value of a number of variables on survival outcome. This was followed by multivariate analysis to identify independent predictors of adverse outcome. A value of P < 0.05 was considered to be statistically significant. Missing data were <10% in all categories (except where specified, i.e. histology and variables for clinical outcomes) and were excluded on a per-analysis basis.
Results

Frequency of CEHAID in AIH
Two hundred and thirty-six of 562 AIH patients (42%) had at least one associated CEHAID. Among these, 168 (29.9%) had one associated CEHAID, 53 (9.4%) had two, 10 (1.8%) had three, 3 (0.5%) had four, and one each had five and seven associated CEHAIDs respectively ( Fig. 1 ).
In total, 58 different diagnoses of CEHAID were identified. Of these, 26/253(10.2%), 89/253(35.2%) and 138/253(54.6%) were diagnosed at presentation, during the follow-up and preceding the diagnosis of AIH, respectively. The chronological diagnosis of 75 CEHAIDs in relation to the diagnosis of AIH were uncertain. The frequency of associated CEHAID in AIH was depicted in Table 1 . Other rarer CEHAIDs are not shown.
Family History of concurrent hepatic and CEHAID in AIH
A positive family history of CEHAID was identified in 92/532 (17.3%) patients with AIH, and of these, 51/92 (55.4%) had concurrent extrahepatic autoimmunity in their personal history. This was significantly more prevalent when compared to patients without family history of CEHAID, 166/440 (37.7%) (p=0.002). Eighty-six patients (86/532, 16.2%) with a
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Clinical patterns of CEHAID in AIH
Autoimmune thyroid disease (AITD) was the commonest CEHAID in AIH patients (18%), followed by connective tissue disorders (12.3%) and autoimmune skin diseases (8%) ( 
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Impact of CEHAID on the clinical course and outcome of AIH
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There were, however, no significant differences between AIH patients with and without CEHAID pertinent to treatment modality utilised, treatment responses, number of relapses and long term clinical outcomes including disease progression, development of HCC and episodes of decompensation leading to LT and liver-related death during the follow-up period (Table 5 ). There was also no significant difference in survival between AIH patients with and without CEHAID (p = 0.563 by log-rank comparison) (Figure 2 ). Although univariate analysis revealed ascites and INR as one of the variables associated with reduced survival, serum albumin at presentation appeared to be an independent predictors of reduced survival following multivariate anlaysis (Table 6) .
Discussions
This is hitherto the largest cohort study to systematically interogate the patterns and clinical impact of CEHAID in patients with AIH. Akin to cohort studies from Italy and Germany (14,15), we recorded a high frequency of CEHAID in AIH (42%), with AITD being the commonest (18%). Additionally, we found that hypothyroidism was more commonly diagnosed than hyperthyrodism and this seemed to be influenced by the type of AIH. Another interesting finding was that autoimmune skin diseases were more frequently associated with AIH-2 than AIH-1. However, this association was not evident in a South American study (13) . On the contrary, the prevalence of skin diseases in our study was comparable to the 
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Interestingly, our data showed that AIH patients with CEHAID tended to present less often with ascites and coagulopathy at presentation compared to patients without CEHAID.
In addition, they were more often had mild fibrosis on histology at diagnosis. Our study is the first to observe this clinical association. There may be two possible hypotheses. Firstly, the presence of CEHAID could have led to an early diagnosis of AIH and rendered a "protective"
effect. This was supported by the observation that more than half of the CEHAID predated INR at diagnosis as the independent predictor for reduced survival (Table 6 ). Therefore,
though the clinical phenotype for AIH patients with CEHAID appears aggressive at presentation, it does not seem to portend poor clinical outcomes.
In a recent study by Muratori et al., more altered liver biochemistry i.e higher serum bilirubin and tramsaminitis, was observed in AIH patients without CEHAID, but no statistical significance was attained (14) . It is worth noting that there was no documentation of coagulation profile, occurrence of ascites and fibrosis stage in their report. They noted that AIH patients with CEHAID tended to be asymptomatic at presentation and they attributed this to a more closer monitoring in this group of patients for other autoimmune diseases, therefore any liver related complications could be detected earlier and associated with ascertainment bias. This could provide a possible account for our findings but we did not observe more asymtomatic patients associated with CEHAID in our cohort.
Whether or not the presence of CEHAID could be a "protective" mechanism to a more aggressive clinical phenotype in AIH at presentation remains to be elucidated.
Nonetheless, this clinical observation may shed light on the intriguing interplay between the shared genetic predisposition of CEHAID and the clinical manifestation of AIH at initial presentation.
The other interesting finding in our study is that SMA positive AIH patients had a lower prevalence of CEHAID than SMA negative patients. It is noteworthy that in another UK population study with PBC, AMA positive PBC patients were also reported to have a significantly lower prevalence of an additional autoimmunity than AMA negative patients (25) . SMA reactivity in titre >1:80 was reported to be associated with evidence of histological disease activity before treatment in a study of 117 patients with AIH (26).
However, in our study, the higher prevalence of SMA reactivity in a titre of >1:80 in AIH patients without CEHAID did not translate to a more severe histological inflammation when compared to patients with CEHAID.
Joint pain has been well-documented as an extrahepatic symptom in 10-60% of AIH patients at index presentation (1, 16, 27, 28) . Arthralgia was reported in 5.2% of our AIH patients. It was the only symptom that was more common in isolation in AIH patients with CEHAID. This is potentially contributed by the presenting symptoms of the concomittant rheumatological diseases as one of the associated CEHAID. In this study, we also demonstrated that CEHAID tended to cluster in female patients. Except for a South American study in which they found no gender predilection for the association of CEHAID (13), our finding was in congruence with previous studies (14, 16, 29, 30) . The difference may be accounted for by the modulation of immune systems by both the hypothalamic-pituitarygonadal system and sex hormones whereby androgens and oestrogens suppress and enhance immunity, respectively (31).
It is well-recognised that patients with autoimmune disease are prone to having additional autoimmune conditions affecting different organs, which may coexist in individual patients and their families (25, 32) . Indeed, the coexistence of concomittant personal or family autoimmunity confers a score of +1 and +2 in the the original and revised IAIHG scoring systems respectively (4, 5) . In our study, 16.2% of AIH patients had family history of CEHAID in first degree relatives, which was in parallel with our previous report with 234 AIH patients (19.6%) (18), but relatively lower when compared to other studies by Van
Gerven et al. and Gregory et al. (42% and 43% respectively) (16, 17) . However, more importantly, we reported that a significantly higher proportion of AIH patients who had a positive family history of CEHAID, had concurrent extrahepatic autoimmunity in their personal history when compared to the counterparts without family history of CEHAID. This association was significantly more evident in first degree relatives than second degree relatives. However, the results may be limited by the retrospective nature of this study whereby the detail documentation of the personal and familial history of CEHAID depends
on individual physicians' discretion. This may potentially lead to underestimate of the real frequency in this cohort. Nevertheless, to our knowledge, this is the first study to demonstrate the close link between personal and familial extrahepatic autoimmunity in an AIH cohort and emphasize the pivotal role of personal and family history of CEHAID in the IAIHG scoring system.
Conclusions
In this study, we have confirmed strong association of extrahepatic autoimmunity in patients with AIH. Recognition of CEHAID is important since it may reflect specific disease phenotypes and serves as a clue for subsequent diagnosis of AIH. Moreover, this study reinforces the close association of extrahepatic autoimmunity among AIH patients and their family. Interestingly, in this study, AIH patients with CEHAID were found to have a lower prevalence of SMA reactivity, less ascites and coagulopathy and milder degree of fibrosis on histology at diagnosis. Although these do not seem to have notable impact on the clinical outcomes of AIH, further evaluation may be warranted to delineate the intricate interplay between extrahepatic autoimmunity and the heterogeneity of clinical phenotype in AIH.
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